Literature DB >> 18757399

Podoplanin is a novel fos target gene in skin carcinogenesis.

Moritz Durchdewald1, Juan Guinea-Viniegra, Daniel Haag, Astrid Riehl, Peter Lichter, Meinhard Hahn, Erwin F Wagner, Peter Angel, Jochen Hess.   

Abstract

Expression and function of the oncogenic transcription factor activator protein (AP-1; mainly composed of Jun and Fos proteins) is required for neoplastic transformation of keratinocytes in vitro and tumor promotion as well as malignant progression in vivo. Here, we describe the identification of 372 differentially expressed genes comparing skin tumor samples of K5-SOS-F transgenic mice (Fos(f/f) SOS(+)) with samples derived from animals with a specific deletion of c-Fos in keratinocytes (Fos(Deltaep) SOS(+)). Fos-dependent transcription of selected genes was confirmed by quantitative real-time PCR analysis using tumor samples and mouse back skin treated with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). One of the most differentially expressed genes encodes the small mucin-like glycoprotein Podoplanin (Pdpn), whose expression correlates with malignant progression in mouse tumor model systems and human cancer. We found Pdpn and Fos expression in chemically induced mouse skin tumors, and detailed analysis of the Pdpn gene promoter revealed impaired activity in Fos-deficient mouse embryonic fibroblasts, which could be restored by ectopic Fos expression. Direct Fos protein binding to the Pdpn promoter was shown by chromatin immunoprecipitation and a TPA-induced complex at a TPA-responsive element-like motif in the proximal promoter was identified by electrophoretic mobility shift assays. In summary, we could define a Fos-dependent genetic program in a well-established model of skin tumors. Systematic analysis of these novel target genes will guide us in elucidating the molecular mechanisms of AP-1-regulated pathways that are critically implicated in neoplastic transformation and/or malignant progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757399     DOI: 10.1158/0008-5472.CAN-08-0299

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17.

Authors:  Juan Guinea-Viniegra; Rainer Zenz; Harald Scheuch; María Jiménez; Latifa Bakiri; Peter Petzelbauer; Erwin F Wagner
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

2.  Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia.

Authors:  Takeshi G Kashima; Arunthati Dongre; Adrienne M Flanagan; Pancras C W Hogendoorn; Richard Taylor; Nicholas A Athanasou
Journal:  Virchows Arch       Date:  2011-04-16       Impact factor: 4.064

3.  Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation.

Authors:  Heike Peterziel; Julia Müller; Andreas Danner; Sebastian Barbus; Hai-Kun Liu; Bernhard Radlwimmer; Torsten Pietsch; Peter Lichter; Günther Schütz; Jochen Hess; Peter Angel
Journal:  Neuro Oncol       Date:  2012-03-06       Impact factor: 12.300

4.  Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations.

Authors:  Matthias Kreppel; Martin Scheer; Uta Drebber; Lutz Ritter; Joachim E Zöller
Journal:  Virchows Arch       Date:  2010-05       Impact factor: 4.064

5.  Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma.

Authors:  Wen-Yu Chuang; Yu-Sun Chang; Yin-Kai Chao; Chi-Ju Yeh; Shir-Hwa Ueng; Chiu-Yueh Chang; Yun-Hen Liu; Chen-Kan Tseng; Hsien-Kun Chang; Yung-Liang Wan; Chuen Hsueh
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

6.  Podoplanin expressing cancer-associated fibroblasts in oral cancer.

Authors:  Harumi Inoue; Hozumi Tsuchiya; Yuji Miyazaki; Kentaro Kikuchi; Fumio Ide; Hideaki Sakashita; Kaoru Kusama
Journal:  Tumour Biol       Date:  2014-08-14

7.  Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma.

Authors:  Akiko Kunita; Takeshi G Kashima; Atsushi Ohazama; Agamemnon E Grigoriadis; Masashi Fukayama
Journal:  Am J Pathol       Date:  2011-06-12       Impact factor: 4.307

8.  Serines in the intracellular tail of podoplanin (PDPN) regulate cell motility.

Authors:  Harini Krishnan; Jhon A Ochoa-Alvarez; Yongquan Shen; Evan Nevel; Meenakshi Lakshminarayanan; Mary C Williams; Maria I Ramirez; W Todd Miller; Gary S Goldberg
Journal:  J Biol Chem       Date:  2013-03-25       Impact factor: 5.157

Review 9.  Podoplanin--a novel marker in oral carcinogenesis.

Authors:  Niharika Swain; Shwetha V Kumar; Samapika Routray; Jigna Pathak; Shilpa Patel
Journal:  Tumour Biol       Date:  2014-06-27

Review 10.  Podoplanin - a small glycoprotein with many faces.

Authors:  Maciej Ugorski; Piotr Dziegiel; Jaroslaw Suchanski
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.